Neuromodulation for the treatment of moderate to severe asthma - a pilot first-in-human clinical study.

IF 1.3 4区 医学 Q3 ALLERGY
Kurt Gehlsen, Angelica Carrasco, Jillian Hooghius, Stephen Pyles
{"title":"Neuromodulation for the treatment of moderate to severe asthma - a pilot first-in-human clinical study.","authors":"Kurt Gehlsen, Angelica Carrasco, Jillian Hooghius, Stephen Pyles","doi":"10.1080/02770903.2025.2531501","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This was a small, uncontrolled, first-in-human clinical study that evaluated the safety and efficacy of neuromodulation in patients with moderate to severe asthma.</p><p><strong>Methods: </strong>Patients diagnosed with chronic intractable pain and moderate or severe asthma on daily asthma medications were tested and subsequently implanted with a permanent spinal cord stimulator. Patients were followed for 12 months and monitored for changes in medication use, asthma control scores, quality of life, exacerbations, ER visits and hospitalizations.</p><p><strong>Results: </strong>11 patients were enrolled, 9 with asthma, and 2 with asthma plus COPD. 91% of patients achieved <i>a</i> > 50% reduction in all asthma medication usage. For all patients enrolled there was an 88% reduction in all asthma medication use and for patients with asthma alone, there was a 98% reduction in all medication use. 100% of enrolled patients reported an Asthma Control Test (ACT) >19 with improved breathing, no wheezing, no chest tightness, and no exacerbations (average increase of 13.3 points). 100% of the enrolled patients reported an improvement in quality of life with an average increase of 3.4 points using the Asthma Quality of Life Questionnaire (AQLQ). No ER visits or hospitalizations were reported due to asthma. There were no adverse events reported.</p><p><strong>Conclusions: </strong>Neuromodulation provided clinically meaningful improvements in asthma symptoms without the need for asthma medications and without adverse events.</p>","PeriodicalId":15076,"journal":{"name":"Journal of Asthma","volume":" ","pages":"1-6"},"PeriodicalIF":1.3000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Asthma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/02770903.2025.2531501","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This was a small, uncontrolled, first-in-human clinical study that evaluated the safety and efficacy of neuromodulation in patients with moderate to severe asthma.

Methods: Patients diagnosed with chronic intractable pain and moderate or severe asthma on daily asthma medications were tested and subsequently implanted with a permanent spinal cord stimulator. Patients were followed for 12 months and monitored for changes in medication use, asthma control scores, quality of life, exacerbations, ER visits and hospitalizations.

Results: 11 patients were enrolled, 9 with asthma, and 2 with asthma plus COPD. 91% of patients achieved a > 50% reduction in all asthma medication usage. For all patients enrolled there was an 88% reduction in all asthma medication use and for patients with asthma alone, there was a 98% reduction in all medication use. 100% of enrolled patients reported an Asthma Control Test (ACT) >19 with improved breathing, no wheezing, no chest tightness, and no exacerbations (average increase of 13.3 points). 100% of the enrolled patients reported an improvement in quality of life with an average increase of 3.4 points using the Asthma Quality of Life Questionnaire (AQLQ). No ER visits or hospitalizations were reported due to asthma. There were no adverse events reported.

Conclusions: Neuromodulation provided clinically meaningful improvements in asthma symptoms without the need for asthma medications and without adverse events.

神经调节治疗中度至重度哮喘-一项首次人体临床试验。
目的:这是一项小型、非对照、首次人体临床研究,旨在评估神经调节治疗中重度哮喘患者的安全性和有效性。方法:诊断为慢性难治性疼痛和每日服用哮喘药物的中度或重度哮喘患者进行测试,随后植入永久性脊髓刺激器。患者随访12个月,监测药物使用、哮喘控制评分、生活质量、病情恶化、急诊室就诊和住院情况的变化。结果:纳入11例患者,其中哮喘9例,哮喘合并COPD 2例。91%的患者实现了所有哮喘药物使用减少50%。对于所有纳入的患者,所有哮喘药物的使用减少了88%,对于单独患有哮喘的患者,所有药物的使用减少了98%。100%的入组患者报告哮喘控制测试(ACT) bbb19,呼吸改善,无喘息,无胸闷,无加重(平均增加13.3分)。使用哮喘生活质量问卷(AQLQ), 100%的入组患者报告生活质量改善,平均增加3.4分。没有因哮喘就诊或住院的报告。无不良事件报告。结论:神经调节在不需要哮喘药物治疗和无不良事件的情况下,对哮喘症状有临床意义的改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Asthma
Journal of Asthma 医学-过敏
CiteScore
4.00
自引率
5.30%
发文量
158
审稿时长
3-8 weeks
期刊介绍: Providing an authoritative open forum on asthma and related conditions, Journal of Asthma publishes clinical research around such topics as asthma management, critical and long-term care, preventative measures, environmental counselling, and patient education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信